Previsioni di mercato dei coniugati di farmaci anticorpali per l\'America del Sud e Centro fino al 2030 - Analisi regionale - per tecnologia (linker scindibile e linker non scindibile), applicazione (cancro del sangue, cancro al seno, cancro ovarico, cancro uroteliale e altri) e canale di distribuzione (ospedale) farmacie, farmacie al dettaglio e farmacie online)
La crescente pipeline di ADC alimenta il mercato dei coniugati di farmaci anticorpali in Sud e Centro America.
Varie aziende biofarmaceutiche stanno sviluppando ADC a causa di il crescente interesse per gli ADC come promettenti trattamenti contro il cancro. Aziende come ImmunoGen, Inc; NBE-Therapeutics, Seagen Inc; Terapie ADC; Merck KGaA; Sorrento Therapeutics, Inc; Terapia mitica; Sutro Biopharma; Picco biologico; Prodotti farmaceutici Regeneron; Asana BioScienze; Sanofi; Navrogen, Inc; e OBI Pharma dispongono di ADC nelle diverse fasi di sviluppo. Si prevede che il lancio commerciale degli ADC sviluppati aumenterà significativamente le dimensioni del mercato.
Le aziende hanno sviluppato un ampio elenco di ADC promettenti nelle diverse fasi cliniche e nelle pipeline da commercializzare. L\'elenco degli ADC in fase di sviluppo comprende Camidanlumab tesirine, ADCT-602, Zynlonta, ADCT-901, ADCT-701, ADCT-212, ADCT-601, Ladiratuzumab Vedotin, NBE-002, IMGN151, IMGN-632, IMGC 936, IMGN -151, OBI 999, R 992, NAV-001, MYTX-011, M1231, STI-6129, Siluro, BCMA ADC, REGN5093-M114, ASN004, TR 1801 ADC.
Le aziende hanno anche condiviso dati preclinici relativi ai rispettivi prodotti. Ad esempio, nell’aprile 2023, Mythic Therapeutics ha annunciato i dati preclinici per il suo MYTX-011 (ADC con targeting cMET). I dati pubblicati includevano i punti salienti di MYTX-011 destinato a trattare un’ampia gamma di tumori cMET+. Allo stesso modo, in occasione del meeting annuale dell’Association for Cancer Research nell’aprile 2023, Araris Biotech AG ha annunciato i suoi dati preclinici sugli ADC anti-Nectin-4 e anti-HER2. I due ADC sono stati sviluppati utilizzando la tecnologia linker proprietaria dell\'azienda. I dati hanno dimostrato una migliore attività antitumorale degli ADC anti-Nectin-4 e anti-HER2 rispetto ai rispettivi ADC approvati dalla FDA in studi in vivo comparativi. Pertanto, l’aumento degli ADC innovativi probabilmente spingerà la crescita del mercato in modo esponenziale nei prossimi anni.
Panoramica del mercato dei coniugati di farmaci anticorpali in America meridionale e centrale
Il mercato dei coniugati di farmaci anticorpali in America meridionale e centrale è segmentato in Brasile, Argentina e nel resto dell\'America meridionale e centrale. La crescita del mercato in questa regione è principalmente attribuita alla crescente consapevolezza riguardo allo screening del cancro. Ad esempio, l’Associazione brasiliana per la prevenzione del cancro intestinale (ABRAPRECI) e il Programma di prevenzione e screening del cancro colorettale sono stati avviati per creare consapevolezza tra le masse. La crescita delle campagne di sensibilizzazione e dei programmi di screening ha aumentato la domanda di servizi di colonscopia. Inoltre, nel dicembre 2020, un\'azienda diagnostica francese, HalioDx, ha firmato un accordo con Diagnosticos da America (DASA) per distribuire il suo test di valutazione del rischio di cancro al colon Immunoscore in Brasile. L\'immunoscore aiuta a prevedere il rischio di recidiva nel cancro del colon in stadio iniziale misurando le risposte immunitarie dell\'ospite nei siti del tumore, il che aiuta a pianificare le strategie di trattamento. Secondo i termini dell\'accordo, in Brasile, la DASA con sede a San Paolo ha i diritti esclusivi di distribuzione del test, offrendolo attraverso 40 reti di laboratori. Poiché gli ADC prendono di mira specifiche cellule tumorali e rilasciano farmaci tossici nelle cellule tumorali, si prevede che l’aumento dei casi di cancro nel paese aumenterà il mercato in futuro. Inoltre, secondo gli attuali piani di screening del cancro del colon-retto in Argentina, si prevede che l\'incidenza del cancro del colon-retto aumenterà a breve a causa della scoperta di malattie precedentemente non diagnosticate. Pertanto, è probabile che questi fattori contribuiscano al progresso del mercato dei coniugati di farmaci anticorpali in Argentina durante il periodo di previsione.
Entrate e previsioni del mercato dei coniugati di farmaci anticorpali per America del Sud e Centro fino al 2030 (milioni di dollari)
Segmentazione del mercato dei coniugati di farmaci anticorpali per America del Sud e Centro
America del Sud e Centrale Il mercato dei coniugati di farmaci anticorpali è segmentato in base alla tecnologia, all’applicazione, al canale di distribuzione e al paese.
Sulla base della tecnologia, il mercato dei coniugati di farmaci anticorpali del Sud e Centro America è biforcato in linker scindibile e linker non scindibile. Il segmento dei linker scindibili ha detenuto una quota maggiore nel 2022.
In base all\'applicazione, il mercato dei coniugati di farmaci anticorpali in Sud e Centro America è segmentato in cancro del sangue, cancro al seno, cancro ovarico, cancro uroteliale e cancro altri. Il segmento del cancro al seno ha detenuto la quota maggiore nel 2022.
In base al canale di distribuzione, il mercato dei coniugati di farmaci anticorpali del Sud e Centro America è segmentato in farmacie ospedaliere, farmacie al dettaglio e farmacie online. Il segmento delle farmacie ospedaliere ha detenuto la quota maggiore nel 2022.
In base al paese, il mercato dei coniugati di farmaci anticorpali dell\'America meridionale e centrale è classificato in Brasile, Argentina e resto dell\'America meridionale e centrale. Il Brasile ha dominato il mercato dei coniugati di farmaci anticorpali in Sud e Centro America nel 2022.
Pfizer Inc, Hoffmann-La Roche Ltd, GSK Plc, Gilead Sciences Inc, AstraZeneca Plc, Astellas Pharma Inc e Takeda Pharmaceutical Co Ltd sono alcuni delle aziende leader che operano nel mercato dei coniugati di farmaci anticorpali del Sud e Centro America.
Table of Content
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Market Attractiveness
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. South & Central America Antibody Drug Conjugates Market - Key Industry Dynamics
4.1 Key Market Drivers:
4.1.1 Growing Strategic Partnerships to Develop Antibody Drug Conjugates
4.1.2 Rising Incidences of Cancer Cases
4.1.3 Increasing FDA Approvals for ADCs
4.2 Market Restraints
4.2.1 High Cost of ADCs Development and Commercialization
4.3 Market Opportunities
4.3.1 Increasing Investments to Develop ADCs
4.4 Market Trends
4.4.1 Escalating Pipeline of ADCs
4.5 Impact Analysis:
5. Antibody Drug Conjugates Market - South & Central America Market Analysis
5.1 South & Central America Antibody Drug Conjugates Market Revenue (US$ Mn), 2017 - 2030
6. South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Technology
6.1 Overview
6.2 South & Central America Antibody Drug Conjugates Market Revenue Share, by Technology 2022 & 2030 (%)
6.3 Cleavable Linker
6.3.1 Overview
6.3.2 Cleavable Linker: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Non-cleavable Linker
6.4.1 Overview
6.4.2 Non-cleavable Linker: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
7. South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Application
7.1 Overview
7.2 South & Central America Antibody Drug Conjugates Market Revenue Share, by Application 2022 & 2030 (%)
7.3 Blood Cancer
7.3.1 Overview
7.3.2 Blood Cancer: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Breast Cancer
7.4.1 Overview
7.4.2 Breast Cancer: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Ovarian Cancer
7.5.1 Overview
7.5.2 Ovarian Cancer: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
7.6 Urothelial Cancer
7.6.1 Overview
7.6.2 Urothelial Cancer: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
7.7 Others
7.7.1 Overview
7.7.2 Others: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
8. South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Distribution Channel
8.1 Overview
8.2 South & Central America Antibody Drug Conjugates Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
8.3 Hospital Pharmacies
8.3.1 Overview
8.3.2 Hospital Pharmacies: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Retail Pharmacies
8.4.1 Overview
8.4.2 Retail Pharmacies: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Online Pharmacies
8.5.1 Overview
8.5.2 Online Pharmacies: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
9. South & Central America Antibody Drug Conjugates Market - Country Analysis
9.1 South & Central America Antibody Drug Conjugates Market, Revenue and Forecast To 2030
9.1.1 Overview
9.1.2 South & Central America Antibody Drug Conjugates Market Breakdown, by Country- Revenue (2022) (US$ Million)
9.1.3 South & Central America: Antibody Drug Conjugates Market, by Countries, 2022 and 2030 (%)
9.1.3.1 Brazil
9.1.3.1.1 Overview
9.1.3.1.2 Brazil: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.1.3 Brazil: Antibody Drug Conjugates Market, by Technology
9.1.3.1.4 Brazil: Antibody Drug Conjugates Market, by Application
9.1.3.1.5 Brazil: Antibody Drug Conjugates Market, by Distribution Channel
9.1.3.2 Argentina
9.1.3.2.1 Overview
9.1.3.2.2 Argentina: Antibody Drug Conjugates Market, by Technology
9.1.3.2.3 Argentina: Antibody Drug Conjugates Market, by Application
9.1.3.2.4 Argentina: Antibody Drug Conjugates Market, by Distribution Channel
9.1.3.3 Rest of South & Central America
9.1.3.3.1 Overview
9.1.3.3.2 Rest of South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.3.3 Rest of South & Central America: Antibody Drug Conjugates Market, by Technology
9.1.3.3.4 Rest of South & Central America: Antibody Drug Conjugates Market, by Application
9.1.3.3.5 Rest of South & Central America: Antibody Drug Conjugates Market, by Distribution Channel
10. Antibody Drug Conjugates Market-Industry Landscape
10.1 Overview
10.2 Organic Growth Strategies
10.2.1 Overview
10.3 Inorganic Growth Strategies
10.3.1 Overview
10.4 Companies' Manufacturing Capacities and Capabilities
11. Company Profiles
11.1 Pfizer Inc
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Hoffmann-La Roche Ltd
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 GSK Plc
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Gilead Sciences Inc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 AstraZeneca Plc
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Astellas Pharma Inc
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Takeda Pharmaceutical Co Ltd
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
12. Appendix
12.1 About Us
12.2 Glossary of Terms
List of Tables
Table 1. South & Central America Antibody Drug Conjugates Market Segmentation
Table 2. New Cancer Cases Worldwide, in 2020
Table 3. List of FDA-Approved ADCs
Table 4. Brazil: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
Table 5. Brazil: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
Table 6. Brazil: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
Table 7. Argentina: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
Table 8. Argentina: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
Table 9. Argentina: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
Table 10. Rest of South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
Table 11. Rest of South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
Table 12. Rest of South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
Table 13. Recent Organic Growth Strategies in Antibody Drug Conjugates Market
Table 14. Recent Inorganic Growth Strategies in the Antibody Drug Conjugates Market
Table 15. Glossary of Terms, Antibody Drug Conjugates Market
List of Figures
Figure 1. South & Central America Antibody Drug Conjugates Market Segmentation, By Country
Figure 2. Key Insights
Figure 3. South & Central America Antibody Drug Conjugates Market - Key Industry Dynamics
Figure 4. Impact Analysis of Drivers and Restraints
Figure 5. South & Central America Antibody Drug Conjugates Market Revenue (US$ Mn), 2017 - 2030
Figure 6. South & Central America Antibody Drug Conjugates Market Revenue Share, by Technology 2022 & 2030 (%)
Figure 7. Cleavable Linker: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Non-Cleavable Linker: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. South & Central America Antibody Drug Conjugates Market Revenue Share, by Application 2022 & 2030 (%)
Figure 10. Blood Cancer: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Breast Cancer: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Ovarian Cancer: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Urothelial Cancer: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Others: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 15. South & Central America Antibody Drug Conjugates Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
Figure 16. Hospital Pharmacies: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Retail Pharmacies: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Online Pharmacies: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 19. South & Central America Antibody Drug Conjugates, by Key Country - Revenue (2022) (US$ Million)
Figure 20. South & Central America: Antibody Drug Conjugates Market, By Key Countries, 2022 And 2030 (%)
Figure 21. Brazil: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. Argentina: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 23. Rest of South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
1. Pfizer Inc
2. Hoffmann-La Roche Ltd
3. GSK Plc
4. Gilead Sciences Inc
5. AstraZeneca Plc
6. Astellas Pharma Inc
7. Takeda Pharmaceutical Co Ltd
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central America antibody drug conjugates market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in South & Central America antibody drug conjugates market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution